Navigation Links
Latest data from Cedars-Sinai vaccine study supports immune targeting of brain tumors
Date:6/16/2011

LOS ANGELES (June 15, 2011) An experimental vaccine developed by researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute targets overactive antigens in highly aggressive brain tumors and improves length of survival in newly diagnosed patients, according to new data that was presented in a poster session at the 47th Annual Meeting of the American Society of Clinical Oncology.

Patients with newly diagnosed glioblastoma multiforme, the most common and aggressive type of tumor originating in the brain, typically live only 12 to 15 months after diagnosis even with standard treatments: surgery, radiation and chemotherapy.

In this Phase I clinical trial that started in November 2006, 11 of 16 patients (69 percent) were still alive at 32 months (a median analysis time); six of 16 (38 percent) continued to be disease-free; three have gone almost four years and another three have survived more than 2.5 years with no recurrence. Median progression-free survival the time from treatment to disease recurrence (median progression-free survival) was 16.9 months.

Phase I trials generally address dosage and safety issues. To further evaluate survival statistics, a randomized, multicenter, placebo-controlled Phase II trial has been launched.

ICT-107 targets six antigens found on glioblastoma cells, three of which also are found on cancer stem cells. Those cells widely are believed to be the original source of tumor cells, enabling them to resist treatment and recur. The study revealed that all 16 patients had at least three of the targeted antigens and 75 percent had all six. Patients who had four of the antigens (MAGE-A1, AIM2, gp100 and HER2) had better immune responses and longer progression-free survival rates.

Surasak Phuphanich, MD, director of the Neuro-Oncology Program of the Department of Neurosurgery and the Department of Neurology at Cedars-Sinai, termed another finding significant: levels of a
'/>"/>

Contact: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Rep. Giffords to Get Skull Patch in Latest Step in Recovery
2. Latest Artificial Pancreas Trials Reduce Risk of Low Blood Sugar
3. Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
4. Latest findings of Dartmouth HIV/AIDS study could turn treatment on its head
5. Lack of health insurance limits hepatitis C patients access to latest antiviral therapy
6. Latest American Chemical Society podcast: Dont blame the pill for estrogen in drinking water
7. New works by UofL professors provide latest oncology reference guides
8. CTO summit and left main coronary interventions course will feature latest research and techniques
9. ASHs 52nd Annual Meeting and Exposition showcases the latest advances in the field
10. Latest American Chemical Society podcast: New water filter kills disease-causing bacteria
11. Latest Findings Back Mammograms for Women in Their 40s
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Universities of Manchester and Auckland suggest that both major forms ... , The findings, published today in the FASEB Journal ... diabetes and type-2 diabetes are both caused by the formation ... , The results, based on 20 years, work in New ... slowed down and potentially reversed by medicines that stop amylin ...
(Date:8/20/2014)... extracted acellular allogeneic nerve, from which Schwann ... been removed, reduced postoperative immune rejection. Simultaneously, ... substrates and base materials, such as the ... provide a good scaffold in the process ... nerve, similar to autologous nerve transplantation, can ...
(Date:8/20/2014)... The Workgroup for Electronic Data ... the use of health IT to create efficiencies ... for its annual fall conference, WEDI-Con 2014: The ... will take place at the HYATT Regency in ... diverse cross-section of payers, providers, government regulators, industry ...
(Date:8/20/2014)... August 20, 2014 If old age is ... cure for it. With extensive research on HGH and stem ... claims to have perfected the art of rubbing off decades ... new younger look with their revolutionary anti-aging hormone therapy and ... 21st century fountain of youth, the MD of MetroMD, Dr ...
(Date:8/20/2014)... The National Association of Hispanic Nurses ... Education Partnership Award (SEPA) grant from the National ... with the Hispanic Communications Network (HCN) entitled Hispanic ... NIH R25 program has been established to address ... health professionals by recruiting and interviewing bilingual role ...
Breaking Medicine News(10 mins):Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3
... 18 Codexis, Inc. today announced that Joseph Sarret, ... Corporate Development from his previous position as Vice President, ... Shaw, Ph.D., President and CEO. Dr. Sarret was ... joined Codexis in 2005 as Corporate Counsel and Director, ...
... Inc. (Nasdaq: MDVN ) today announced ... U.S. Food and Drug Administration (FDA) to begin ... novel androgen receptor antagonist, in patients with metastatic ... chemotherapy. The placebo-controlled, double-blind, multinational trial will ...
... smaller and more contained, study finds , , WEDNESDAY, March 18 ... reduce the risk of death by as much as half, ... information on 1,044 women who were seen at a medical ... had developed a second breast cancer -- 455 with cancer ...
... PHR Taps into Latino Market Underserved by ... Information Systems, Inc. (OTC Bulletin Board: FVRL), ... Inc. (collectively, "MMR") provides consumer-controlled Personal Health ... safe deposit box storage solutions ( www.myesafedepositbox.com ...
... 18 Kensey Nash Corporation (Nasdaq: KNSY ) ... stock repurchase. The new program allows the Company to ... and outstanding shares of Common Stock and has no scheduled ... its available cash. "Given our strong cash position and the ...
... they learned from elders who have been through economic ... simply being thankful can calm economic anxiety; other key ... optimism; what to avoid?: elders say don,t listen to ... released in conjunction with national conference Aging in America ...
Cached Medicine News:Health News:Codexis Names Sarret SVP, Corporate Development 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 2Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 3Health News:Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer 4Health News:When Breast Cancer Recurs, Finding Pre-Symptoms Is Key 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 2Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 3Health News:MMR Information Systems Offers First Bilingual Personal Health Record Through The Latino Coalition 4Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 2Health News:Kensey Nash Announces 600,000 Share Stock Repurchase Program 3Health News:New Survey: Top Lesson from Seniors About Economic Worries? Gratitude Trumps Fear 2
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: